The mysterious case of Viatris and the missing insulin label deepens

Viatris and the case of the missing insulin label is getting a second act.

Mylan Pharmaceuticals, now flying the Viatris banner, said Tuesday that it was recalling one lot of insulin glargine injection—the companies’ interchangeable biosimilar to Sanofi’s blockbuster diabetes med Lantus.